Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IBRX

ImmunityBio Inc

Dec 12 • 11:44AM ET

3.16

Dollar change +0.01
Percentage change 0.32	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX NVAX PFE VRTX REGN GILD ALNY AMGN BIIB

| Held by: VTI VB XBI IWM VBK VXF IWO SCHA VTWO VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.89	Insider Own	77.07%	Shs Outstand	696.83M	Perf Week	-30.85%
Market Cap	2.20B	Forward P/E	-	EPS next Y	-0.67	Insider Trans	0.00%	Shs Float	159.81M	Perf Month	-36.16%
Income	-587.79M	PEG	-	EPS next Q	-0.22	Inst Own	9.89%	Short Float	31.15%	Perf Quarter	-11.73%
Sales	7.33M	P/S	300.41	EPS this Y	27.54%	Inst Trans	10.57%	Short Ratio	8.96	Perf Half Y	-46.17%
Book/sh	-1.07	P/B	-	EPS next Y	19.20%	ROA	-147.50%	Short Interest	49.78M	Perf Year	-15.05%
Cash/sh	0.19	P/C	16.89	EPS next 5Y	-1.70%	ROE	-	52W Range	3.06 - 10.53	Perf YTD	-37.05%
Dividend Est.	-	P/FCF	-	EPS past 5Y	1.17%	ROI	-222.32%	52W High	-69.99%	Beta	0.63
Dividend TTM	-	Quick Ratio	2.64	Sales past 5Y	195.19%	Gross Margin	-145.23%	52W Low	3.27%	ATR (14)	0.46
Dividend Ex-Date	-	Current Ratio	2.68	EPS Y/Y TTM	17.24%	Oper. Margin	-4900.23%	RSI (14)	30.10	Volatility	8.04% 8.09%
Employees	628	Debt/Eq	-	Sales Y/Y TTM	1218.71%	Profit Margin	-8016.83%	Recom	1.67	Target Price	14.25
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	25.13%	Payout	-	Rel Volume	1.96	Prev Close	3.15
Sales Surprise	108.75%	EPS Surprise	21.35%	Sales Q/Q	7346.34%	Earnings	Nov 12 BMO	Avg Volume	5.56M	Price	3.16
SMA20	-33.18%	SMA50	-30.35%	SMA200	-40.16%	Trades		Volume	4,096,327	Change	0.32%

Date	Action	Analyst	Rating Change	Price Target Change
May-12-23	Downgrade	Piper Sandler	Overweight → Neutral	$10 → $4
Aug-03-22	Initiated	Jefferies	Buy	$8

Today 08:00AM	D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering (GlobeNewswire)
Dec-11-24 07:30AM	ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock (Business Wire) -32.11%
Dec-10-24 04:24PM	ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-23-24 10:24AM	Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-21-24 10:00AM	ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment (PR Newswire)
08:00AM	Loading…
Nov-19-24 08:00AM	ImmunityBio Completes ANKTIVAs Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months (Business Wire) +6.79%
Nov-14-24 08:00AM	Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon (PR Newswire)
Nov-12-24 07:15AM	ImmunityBio Reports Third-Quarter 2024 Financial Results (Business Wire) -9.17%
Oct-25-24 03:22PM	ImmunityBio Soars 56% in a Day: Is This Cancer Breakthrough the Next $30 Stock? (GuruFocus.com) +26.37%
Oct-24-24 09:00AM	First Patients Dosed in Phase 1 Clinical Study of ImmunityBios CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma (Business Wire) +21.68%
Oct-21-24 09:00AM	ImmunityBio to Participate in the Jefferies London Healthcare Conference (Business Wire)
Sep-09-24 08:30AM	ImmunityBio Presents Positive Long-Term Overall Survival Datain Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA and Checkpoint Immunotherapyat WorldConferenceonLungCancer (Business Wire) +5.03%
Aug-12-24 08:46AM	ImmunityBio's ANKTIVA Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval (Business Wire)
Aug-06-24 09:00AM	ImmunityBio Announces Study of ANKTIVA in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer (Business Wire)
Jul-01-24 03:26AM	Notice to Long-Term Shareholders of ImmunityBio, Inc. (IBRX): Grabar Law Office Is Investigating Claims on Your Behalf (Newsfile)
09:41AM	Loading…
Jun-26-24 09:41AM	ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why (Zacks) -6.88%
Jun-20-24 09:00AM	ImmunityBio Announces Insurance Coverage of ANKTIVA Across Multiple States with First Commercial Doses Administered Just Weeks After FDA ApprovalOpening New Era for Immunotherapy Beyond Checkpoint Inhibitors (Business Wire)
06:15AM	3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions (InvestorPlace)
Jun-07-24 09:13AM	ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update (Business Wire)
May-17-24 09:00AM	Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast (Business Wire)
May-10-24 09:53AM	IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
May-09-24 06:01AM	The 3 Best Bargain Stocks to Buy in May 2024 (InvestorPlace)
May-07-24 08:00AM	ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA (Business Wire) +5.76%
May-06-24 06:00AM	Even Worse than Gamestop? 3 Meme Stocks That Are Screaming Sells (InvestorPlace) -14.64%
May-02-24 04:04PM	ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types (Business Wire) +5.04%
May-01-24 10:05AM	Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 (PR Newswire) +6.88%
Apr-30-24 08:00AM	ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA Approval in Fireside Chat at the Annual Conference of the American Urological Association (Business Wire) -11.12%
Apr-25-24 12:03AM	ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer (Business Wire) +6.02%
Apr-23-24 04:55PM	ImmunityBio's bladder cancer therapy wins FDA approval (Yahoo Finance Video) +11.13% -12.20%
Apr-22-24 09:56PM	ImmunityBio Announces FDA Approval of ANKTIVA, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (Business Wire) -6.26%
11:02AM	Loading…
Apr-19-24 11:02AM	12 Most Shorted Stocks in 2024 (Insider Monkey) +7.33%
Mar-19-24 09:53PM	IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) +10.31%
Mar-14-24 08:45AM	Biotech's Role in Addressing the Pancreatic Cancer Emergency (PR Newswire)
Mar-06-24 09:00AM	NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy (Business Wire) +5.39%
Mar-05-24 09:00AM	N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study (Business Wire)
Feb-21-24 09:00AM	ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial (Business Wire)
Feb-05-24 09:00AM	ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG (Business Wire)
Jan-02-24 07:10AM	ImmunityBio inoculates itself against financial pain, inking $210M royalty deal to get cancer drug to market (FierceBiotech.com)
06:00AM	ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million (Business Wire)
Nov-16-23 09:00AM	ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-07-23 09:00AM	First Data for ImmunityBios Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity (Business Wire)
Oct-26-23 09:00AM	FDA Accepts ImmunityBios BLA Resubmission as Complete and Sets New PDUFA Date (Business Wire) +29.75%
Oct-23-23 09:00AM	ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ (Business Wire) +10.00%
Oct-09-23 08:45AM	Lawsuit Notice: Investors who lost money with ImmunityBio, Inc. (NASDAQ: IBRX) shares should contact the Shareholders Foundation (GlobeNewswire)
Sep-11-23 06:00AM	ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities (Business Wire) +19.38%
Aug-03-23 09:00AM	ImmunityBio Names Enrique Diloné as Chief Technology Officer (Business Wire) +9.02%
Jul-20-23 08:32PM	ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors (Business Wire) -6.77%
Jul-10-23 09:30AM	Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients (Business Wire)
May-22-23 09:00AM	ImmunityBio to Participate in the Jefferies Global Healthcare Conference (Business Wire) -6.06%
Apr-25-23 09:00AM	National Multicenter Trial Opens to Study ImmunityBios Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome (Business Wire)
Apr-24-23 11:28PM	ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services University (Business Wire) -8.96%
Feb-16-23 09:00AM	ImmunityBio to Present Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15RFc superagonist N-803 plus BCG at ASCO GU (Business Wire) -7.71%
Feb-15-23 09:00AM	ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors (Business Wire) -6.42%
Jan-19-23 09:00AM	ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration (Business Wire)
Dec-12-22 08:30AM	ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor (Business Wire) +10.08%
Nov-17-22 09:00AM	ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-10-22 05:21PM	NEJM Evidence Publishes Results for ImmunityBios QUILT 3.032 Registrational Trial of IL-15 Superagonist N-803 Plus BCG in Patients with Bladder Cancer (Business Wire) +20.23% +11.66%
Oct-27-22 08:00AM	ImmunityBio to Participate in the Jefferies London Healthcare Conference (Business Wire)
Jul-28-22 04:18PM	ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ (Business Wire) -9.11%
Jul-26-22 04:17PM	Fauci on needing a second generation of COVID vaccines: 'We have multiple variants of concern ... And it's getting more complicated' (Yahoo Finance)
Jun-30-22 10:00AM	ImmunityBio may have saved the day in Dunkirk, but it faces the same challenges as Athenex (American City Business Journals)
Jun-14-22 11:25AM	Health authorities push for a vaccine patent waiver to 'genuinely' prepare for the next pandemic (Yahoo Finance)
Jun-06-22 09:00AM	ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting (Business Wire)
May-23-22 08:32AM	ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ (Business Wire)
May-16-22 07:29AM	What Percentage Of ImmunityBio, Inc. (NASDAQ:IBRX) Shares Do Insiders Own? (Simply Wall St.) +11.46%
Apr-28-22 09:00AM	ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
Apr-25-22 09:00AM	ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer (Business Wire)
Apr-01-22 04:15PM	ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ (Business Wire) +5.68%
Mar-02-22 09:00AM	Memory Cytokine-Enhanced Natural Killer Cells Show Promising Results in Leukemia Patients; Data Support ImmunityBios Scaled m-ceNK Clinical Program (Business Wire)
Feb-21-22 09:32AM	'The idea that there's not enough human capital in South Africa is outrageous': Dr. Patrick Soon-Shiong (Yahoo Finance)
Feb-18-22 12:13PM	Biden's renewed cancer moonshot is 'laudable effort': Dr. Patrick Soon-Shiong (Yahoo Finance)
Feb-15-22 09:00AM	ImmunityBio Completes Acquisition of Athenexs Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility (Business Wire) +22.26%
09:00AM	Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility (GlobeNewswire)
Feb-14-22 05:17PM	ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New Magnitude of Benefit in Patients with BCG Unresponsive Bladder Cancer (Business Wire)
Jan-31-22 07:16PM	ImmunityBio Announces Promising Clinical Study Results for Kick and Kill HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy (Business Wire) +12.57%
Jan-21-22 09:38PM	Liberty One Investment Management, Llc Buys Fastly Inc, Kratos Defense & Security Solutions ... (GuruFocus.com) +5.35%
Jan-19-22 07:34AM	Billionaire Soon-Shiong Launches 1 Billion-Dose Vaccine Plant in Cape Town (Bloomberg)
Jan-18-22 06:00PM	ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival (Business Wire) -7.20%
Jan-13-22 09:00AM	Inside the Athenex-ImmunityBio deal and the California company's employment plans (American City Business Journals)
Jan-12-22 08:30AM	ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness (Business Wire)
08:30AM	Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility (GlobeNewswire)
Jan-04-22 09:00AM	ImmunityBio Awarded Seminal Patent on Natural Killer Cells (Business Wire) -6.91%
Jan-03-22 08:00AM	AMYRIS AND IMMUNITYBIO COMPLETE JOINT VENTURE FOR NEXT GENERATION COVID-19 RNA VACCINE (PR Newswire) +23.85%
Dec-20-21 09:00AM	ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing (Business Wire)
Dec-07-21 06:38AM	What Type Of Shareholders Own The Most Number of ImmunityBio, Inc. (NASDAQ:IBRX) Shares? (Simply Wall St.) +5.80%
Nov-18-21 09:00AM	ImmunityBio Expands Vaccine Program to Accelerate Use of "Mix-and-Match" Technologies in Developing and Manufacturing Next-Generation COVID-19 Vaccines (Business Wire) -6.31%
Nov-08-21 05:14PM	Amyris takes bite out of sharks with Covid vaccine joint venture (American City Business Journals)
08:00AM	Amyris Announces JV Partnership With ImmunityBio For Next Generation COVID-19 RNA Vaccine (PR Newswire)
Nov-04-21 09:00AM	ImmunityBio to Present at the Jefferies London Healthcare Conference (Business Wire)
Oct-19-21 09:00AM	ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease (Business Wire)
Oct-13-21 09:00AM	ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients90% of Patients Have Exceeded Historical Survival Rates to Date (Business Wire)
Oct-04-21 08:30AM	National Cancer Institute Selects ImmunityBios N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy (Business Wire)
Sep-13-21 08:30AM	ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial (Business Wire)
Sep-07-21 08:30AM	ImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives (Business Wire)
Sep-01-21 09:00AM	ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Associations Annual Meeting (Business Wire)
Aug-16-21 09:00AM	ImmunityBio Appoints Dr. Patrick Soon-Shiong to Global Chief Scientific and Medical Officer; Newly Created Role Will Lead Companys Scientific Strategy and Global Expansion (Business Wire)
Jul-27-21 09:00AM	ImmunityBios Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a U.S. Patent (Business Wire)
Jul-14-21 09:00AM	ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19 (Business Wire)
Jun-28-21 09:00AM	ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients (Business Wire) +5.33%
Jun-23-21 04:05PM	Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee (GlobeNewswire)

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
Adcock Richard	CEO & President	Feb 05 '24	Option Exercise	83,334	286,303	Feb 06 09:14 PM
Simon Barry J.	Director	Jan 31 '24	Option Exercise	57,200	3,145,855	Feb 02 07:38 PM
Sachs David C.	Chief Financial Officer	Jan 31 '24	Option Exercise	70,745	212,673	Feb 02 07:33 PM
LAUER REGAN J	Chief Accounting Officer	Jan 31 '24	Option Exercise	32,872	107,804	Feb 02 07:32 PM
Sachs David C.	Chief Financial Officer	Dec 31 '23	Option Exercise	30,397	152,439	Jan 03 09:41 PM
Adcock Richard	CEO & President	Dec 31 '23	Option Exercise	34,483	220,065	Jan 03 09:40 PM
LAUER REGAN J	Chief Accounting Officer	Dec 15 '23	Option Exercise	21,030	74,932	Dec 19 04:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IBRX

ImmunityBio Inc

Upgrade your FINVIZ experience